Search NewsRoom

Advanced Search >

Crowell & Moring's Litigation Forecast 2022

BioPharma – The Calm Between the CRISPR Storms

Contributors: Anne Li

January 12, 2022

[Article PDF]

The next CRISPR dustup is likely to be even bigger, with many more players

For nearly 10 years, the story of CRISPR litigation has unfolded as an epic battle between two sides. Now, the conflict is poised to erupt again, but this time as a full-fledged fracas with a multitude of players, and it could take another decade to sort out, says Anne Li, a partner in Crowell & Moring’s Life Sciences Litigation, Intellectual Property, and Trade Secrets groups

Scientists have known about CRISPR—clustered regularly inter-spaced short palindromic repeats—in DNA for decades. It wasn’t until 2011, however, that researchers affiliated with the University of California were able to harness that knowledge to successfully edit DNA using CRISPR along with its associated enzyme known as Cas9. In 2012, UC announced it had successfully used the tool to cut DNA, using bacterial cells known as prokaryotic cells.

Read the complete article in the Litigation Forecast 2022

Anne Elise Herold Li
Partner – New York
Phone: +1.212.895.4279

Index: Litigation Forecast 2022

Litigation Forecast Archive:
20212020, 2019, 2018, 2017

Regulatory Forecast Archive: 2020, 2019, 20182017